Albert Bourla, Pfizer CEO (Markus Schreiber/AP Images)
January 30, 2024 07:32 AM ESTUpdated 08:03 AM
Pharma

Pfiz­er's Q4 rev­enue tum­bles 42% amid Covid re­set

Katherine Lewin

News Reporter

Pfiz­er round­ed out a tough year with fourth-quar­ter rev­enue of $14.2 bil­lion, a 42% de­crease com­pared to the same time in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

A service from the Financial Times